ABVC BioPharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Net Income	-10.52	-16.42	-12.84	-9.79	-3.64
Depreciation & Amortization	0.03	0.02	0.01	0.04	0.06
Share-Based Compensation	1.64	7.04	5.31	4.15	0.02
Other Operating Activities	4.62	1.96	-0.08	1.04	0.43
Operating Cash Flow	-4.24	-7.4	-7.6	-4.56	-3.13
Capital Expenditures	-0.02	-0.12	-0.02	0	0
Acquisitions	0	0	0	-0.37	-0.02
Change in Investments	-0.34	-1.6	-0.79	0.15	-0.02
Investing Cash Flow	-0.36	-1.72	-0.81	-0.23	-0.04
Share Issuance / Repurchase	3.46	3.66	11.12	7.62	0.53
Debt Issued / Paid	0.46	0.35	-0.27	1.95	2
Other Financing Activities	-	-	-0.85	-	0.55
Financing Cash Flow	3.92	4.01	10	9.57	3.09
Exchange Rate Effect	0	-0.07	-0.03	0.06	-0
Net Cash Flow	-0.67	-5.17	1.56	4.84	-0.08
Free Cash Flow	-4.26	-7.52	-7.62	-4.56	-3.13
Free Cash Flow Margin	-2792.79%	-775.23%	-2140.33%	-944.82%	-446.69%
Free Cash Flow Per Share	-0.98	-2.37	-3.04	-2.31	-1.79

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).